SIGA Technologies, Inc.

NASDAQ•SIGA

CEO: Dr. Dennis E. Hruby Ph.D.

板块: Healthcare

行业: Drug Manufacturers - Specialty & Generic

上市日期: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

联系方式

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

市值

$446.85M

市盈率 (TTM)

6.0

37.5

股息率

9.6%

52周最高

$9.62

52周最低

$4.95

52周范围

28%

排名30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

基于 10 年期基本面

一般 • 5.1 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2016-2025

财务仪表盘

Q3 2025 数据

营业收入

$2.62M-73.83%

近4季度走势

每股收益

-$0.09-578.72%

近4季度走势

自由现金流

-$10.10M+36.43%

近4季度走势

2025 Q3 财报亮点

核心亮点

Nine Month Revenue Surge Total revenues reached $90.78M USD for nine months, up $33.53M USD from $57.25M USD reported in prior year.

Net Income Improvement Nine-month net income $28.71M USD, significantly exceeding $13.45M USD reported in the comparable nine-month period.

Strong Operating Cash Flow Operating cash flow provided $60.33M USD for nine months, reversing prior year's $7.55M USD cash usage.

Liquidity Position Strengthened Cash and equivalents total $171.96M USD as of September 30, 2025, compared to $155.40M USD at year-end 2024.

关注风险

EMA Mpox Review Status EMA reassessment procedure ongoing regarding Tecovirimat-SIGA effectiveness for mpox treatment indications, potentially impacting authorization.

Quarterly Revenue Decline Quarterly revenue fell sharply to $2.62M USD in Q3 2025 from $10.01M USD in Q3 2024, resulting in a net loss.

Government Shutdown Uncertainty Prolonged U.S. Government shutdown risks delaying funding decisions, new contract awards, and suspending ongoing contract work.

Tariff Cost Increase Risk Tariff activity involving U.S. and Europe may materially increase IV TPOXX® overall manufacturing costs, impacting margins.

前瞻展望

Smallpox PEP Submission Target Targeting Supplemental NDA submission for oral TPOXX® smallpox post-exposure prophylaxis indication in 2026 based on trial results.

Unexercised BARDA Options Unexercised BARDA options total $5.6M USD, but these supportive activities are currently not expected to be required by BARDA.

Future Purchase Commitments Outstanding purchase orders associated with manufacturing obligations total approximately $12.5M USD as of September 30, 2025.

New Accounting Standard Review Evaluating impact of recently issued FASB ASU 2024-03 regarding expense disaggregation disclosures effective in future periods.

同行对比

营业收入 (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$680.39M

+4.4%

毛利率 (最新季度)

CTMX

100.0%

+0.0pp

RIGL

91.5%

+7.7pp

KALV

91.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
OLMA	$1.77B	-12.9	-41.5%	1.3%
VTYX	$1.00B	-9.4	-48.1%	4.7%
KALV	$819.36M	-4.2	-282.0%	44.0%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-68.2%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

75%

现金流波动较大

深度研究

下次财报:2026年3月9日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据